Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial
19 Abril 2021 - 9:00AM
Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of
innovative technology that enables the functional selection of stem
cells, today announced positive data from the Company's open label
Phase 1/2 clinical trial of its ApoGraft™ technology in Israel. All
eleven patients enrolled for the trial were transplanted using the
ApoGraft product and were engrafted in a timely manner. The primary
objective, safety and tolerability of ApoGraft administered to
patients with hemato-oncology disorders, was met and there were no
procedure related adverse events (AEs) reported during the course
of the study.
As previously announced last month, following
the anticipated closing of the merger with Quoin Pharmaceuticals,
the development of the ApoGraft technology is expected to be
pursued by San-Diego based EnCellX, led by Adi Mohanty.
“The data validates earlier results and supports
the ongoing development of our products,” commented Dr. Shai
Yarkoni, Chief Executive Officer. “I remain committed and
believe that the human data from this study will expedite the
clinical development of the ApoGraft.”
About Cellect Biotechnology
Ltd.
Cellect Biotechnology (APOP) has developed a breakthrough
technology for the selection of stem cells from any given tissue
that aims to improve a variety of cell-based therapies.
The Company's technology is expected to provide
researchers, clinicians and pharmaceutical companies with the tools
to rapidly isolate specific cells in quantity and quality, allowing
cell-based treatments and procedures in a wide variety of
applications in regenerative medicine. The Company's current
clinical trial is aimed at bone marrow transplantations in cancer
treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company's ability to continue as a going concern; or maintain its
current operations; uncertainties involving any strategic
transaction the Company may decide to enter into as the result of
its current efforts to explore new strategic alternatives;
uncertainties of cash flows and inability to meet working capital
needs; the Company's ability to obtain regulatory approvals; the
Company's ability to obtain favorable pre-clinical and clinical
trial results; the Company's technology may not be validated and
its methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual
Report on Form 20-F for the fiscal year ended December 31, 2020
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC.
ContactCellect Biotechnology
Ltd.Eyal Leibovitz, Chief Financial
Officerwww.cellect.co+972-9-974-1444Or
EVC Group LLC Michael Polyviou(732)
933-2754mpolyviou@evcgroup.com
Cellect Biotechnology (NASDAQ:APOP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cellect Biotechnology (NASDAQ:APOP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024